Thyroid Cancer

Thymic Carcinoma: Pembrolizumab May Be An Effective Option

Thymic Carcinoma: Pembrolizumab May Be An Effective Option

By

Thymic carcinomas typically express high levels of PD-L1, leading researchers to predict a positive response to pembrolizumab.

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

By

The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.

Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment

Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment

By

Researchers enrolled 116 patients who were diagnosed with or were suspected of having thyroid cancer. The authors measured the growths' change in diameter to determine a growth pattern.

Dabrafenib Plus Trametinib May Be Effective Therapy for Thyroid Cancer

Dabrafenib Plus Trametinib May Be Effective Therapy for Thyroid Cancer

By

Patients with ATC have a very poor prognosis and are left with few systemic therapy options.

Cabozantinib Effective as Salvage Therapy in Thyroid Cancer

Cabozantinib Effective as Salvage Therapy in Thyroid Cancer

By

Significant clinical benefit was found in some patients treated with cabozantinib in the salvage setting.

USPSTF Recommends Against Thyroid Cancer Screening

USPSTF Recommends Against Thyroid Cancer Screening

By

The USPSTF stated that there was inadequate direct evidence for the benefits of screening.

Regorafenib Phase 2 Trial for Metastatic Medullary Thyroid Cancer

Regorafenib Phase 2 Trial for Metastatic Medullary Thyroid Cancer

By

Researchers are studying regorafenib, a multi kinase inhibitor, as treatment for metastatic medullary thyroid cancer.

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

Young Thyroid Cancer Survivors: Increased Risk of Heart Disease, Osteoporosis

By

Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.

RT Dose Associated With Improved Anaplastic Thyroid Cancer Survival

RT Dose Associated With Improved Anaplastic Thyroid Cancer Survival

By

Patients with unresected anaplastic thyroid carcinoma who receive greater than 60 Gy of radiation appear to have a longer median overall survival.

Crohn Disease and Thyroid Cancer: An Increased Risk?

Crohn Disease and Thyroid Cancer: An Increased Risk?

By

Crohn Disease (CD) may increase one's risk of thyroid cancer, according to an article published in Inflammatory Bowel Diseases.

USPSTF on Asymptomatic Thyroid Cancer: Do Not Screen Population

USPSTF on Asymptomatic Thyroid Cancer: Do Not Screen Population

By

The USPSTF recommends against population-wide screening for asymptomatic thyroid cancer.

Patient Age Linked With Survival in Papillary Thyroid Cancer

Patient Age Linked With Survival in Papillary Thyroid Cancer

For papillary thyroid cancer (PTC), patient age is associated with death in a linear fashion, with no apparent age cut point demarcating survival difference.

Genomic Information and the Future of Health Care

Genomic Information and the Future of Health Care

By

Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.

Thyroid Carcinoma Treatment Regimens

Thyroid Carcinoma Treatment Regimens

Find information about available non-chemotherapy treatments for thyroid carcinoma, including total thyroidectomy, radiodine treatment, and ablation.

The Role of Microbes in Oncogenesis and the Treatment of Cancer

The Role of Microbes in Oncogenesis and the Treatment of Cancer

By

Researchers are identifying new roles for infectious and commensal microbes in facilitating and inhibiting carcinogenesis.

Two Genetic Mutations Linked to Tumor Behavior in Thyroid Cancer Patients

Two Genetic Mutations Linked to Tumor Behavior in Thyroid Cancer Patients

By

CDC27 mutations may be associated with less aggressive behavior while SLC25A5 mutations may be associated with more aggressive behavior in papillary thyroid carcinomas.

New Agent May Offer Hope in Treating Thyroid Cancer

New Agent May Offer Hope in Treating Thyroid Cancer

By

The first-in-class compound CUDC-907 may be promising for anaplastic thyroid cancer and poorly differentiated thyroid cancer.

Recurrence Rates Low After rhTSH for Postoperative Ablation in Low-Risk Thyroid Cancer

Recurrence Rates Low After rhTSH for Postoperative Ablation in Low-Risk Thyroid Cancer

By

Long-term recurrence rates appear to be low following the use of recombinant human thyrotropin for postoperative ablation in low-risk thyroid cancer.

Sequential Combination Strategy May Be Optimal in Advanced Thyroid Cancer

Sequential Combination Strategy May Be Optimal in Advanced Thyroid Cancer

By

Initiating treatment with the mTor inhibitor everolimus followed by the somatostatin analogue pasireotide may be beneficial in advanced thyroid cancer.

Active Surveillance May Be Appropriate in Select Thyroid Cancer Patients

Active Surveillance May Be Appropriate in Select Thyroid Cancer Patients

By

Active surveillance in low-risk thyroid cancer may be better than immediate surgery in some patients.

Close Monitoring May Improve Outcomes With Lenvatinib in Differentiated Thyroid Cancer

Close Monitoring May Improve Outcomes With Lenvatinib in Differentiated Thyroid Cancer

By

Despite side effects, patients with differentiated thyroid cancer taking lenvatinib may experience better outcomes with close monitoring.

Liquid Biopsy May Help Predict Survival in Medullary Thyroid Carcinoma

Liquid Biopsy May Help Predict Survival in Medullary Thyroid Carcinoma

By

Liquid biopsy may prevent the need for unnecessary biopsies in patients with medullary thyroid carcinoma.

Everolimus Associated With Longest mOS Observed Among Patients With Advanced pNET

Everolimus Associated With Longest mOS Observed Among Patients With Advanced pNET

By

Treatment with everolimus in the RADIANT-3 trial was associated with a median overall survival of 44 months.

Overdetection Explains Increased Prevalence of Thyroid Cancer

Overdetection Explains Increased Prevalence of Thyroid Cancer

Despite reports to the contrary, the prevalence of differentiated thyroid cancer is not increasing.

Mortality Risk Higher With Genetic Duet in Papillary Thyroid Cancer

Mortality Risk Higher With Genetic Duet in Papillary Thyroid Cancer

By

The risk of mortality is higher for patients with papillary thyroid cancer who harbor both BRAF V600E and TERT promoter mutations.

Risk Estimates Identified for Occult Nodal Disease in Thyroid Cancer After Surgery

Risk Estimates Identified for Occult Nodal Disease in Thyroid Cancer After Surgery

By

Researchers have identified estimates for risk of occult nodal disease of patients with papillary thyroid cancer who have undergone surgery.

Vemurafenib Active in Progressive, RAI-refractory Papillary Thyroid Cancer

Vemurafenib Active in Progressive, RAI-refractory Papillary Thyroid Cancer

By

Vemurafenib showed activity in patients with progressive BRAFV600E mutation-positive papillary thyroid cancer refractory to radioactive iodine.

Imaging After Thyroid Cancer Treatment May Not be Beneficial

Imaging After Thyroid Cancer Treatment May Not be Beneficial

More imaging tests after treatment does not always lead to an improvement in thyroid cancer patients' chances of survival.

Papillary Thyroid Cancer: Radiographic SLNB May Lead to Management Change

Papillary Thyroid Cancer: Radiographic SLNB May Lead to Management Change

By

The use of the radioguided sentinel lymph node biopsy (rSLNB) technique may lead to management change in more than 33% of patients with papillary thyroid cancer.

Drug, Genomic Innovations Have Transformed Thyroid Cancer Treatment

Drug, Genomic Innovations Have Transformed Thyroid Cancer Treatment

By

There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs